Summary:
An Open-label, 8-Week Study of Safety and Efficacy of Pimavanserin
Treatment in Adults With Parkinson’s Disease and Depression
Qualified Participants Must:
Patient is a male or female 50 years of age or older
Has a clinical diagnosis of idiopathic Parkinson's disease with a minimum duration of 1 year
Qualified Participants May Receive:
Compensation for time and travel